[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100456347":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":15,"locations":7,"responsibleParty":24,"collaborators":7,"id":26,"slug":7,"hasResults":27,"nctId":28,"briefTitle":29,"officialTitle":29,"acronym":7,"eligibilityCriteria":30,"healthyVolunteers":27,"sex":31,"minAge":32,"maxAge":7,"enrollmentInfo":7,"targetDuration":7,"studyType":33,"phases":7,"briefSummary":34,"conditions":35,"keywords":38,"overallStatus":43,"whyStopped":7,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":7,"completionDateStruct":7,"leadSponsor":48,"locationsCount":7},{"fullName":5,"class":6},"Novartis","INDUSTRY",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":13},"DRUG","Iptacopan","Patients receive Iptacopan",[14],"LNP023",[16,21],{"name":17,"role":18,"phone":19,"phoneExt":7,"email":20},"MAP requests are initiated by a licensed physician.https:\u002F\u002F www.novart is.com\u002Fhealthcare-professionals\u002Fmanaged-access-programs","CONTACT","1-888-669-6682","novartis.email@novartis.com",{"name":22,"role":18,"phone":23,"phoneExt":7,"email":7},"Novartis Pharmaceuticals","+41613241111",{"type":25,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100456347",false,"NCT05222412","Managed Access Programs for LNP023, Iptacopan","Inclusion Criteria:\n\n* An independent request should be received from a licensed physician (in some instances from Health Authorities, Institutions or Governments).\n* The patient has a serious or life-threatening disease or condition and no comparable or satisfactory alternative therapy is available for diagnosis, monitoring or treatment; patient is not medically eligible for available treatment alternatives or has exhausted all available treatment options.\n* The patient is not eligible or able to enroll in a Novartis clinical trial or continue participation in a Novartis clinical trial.\n* There is a potential patient benefit to justify the potential risk of the treatment use, and the potential risk is not unreasonable in the context of the disease or condition to be treated.\n* The patient must meet any other medical criteria established by the medical experts responsible for the product or by the Health Authority in a country (as applicable).\n* Provision of the product will not interfere with the initiation, conduct or completion of a Novartis clinical trial or overall development program.\n* Managed access provision is allowed per local laws\u002Fregulations.","ALL","18 Years","EXPANDED_ACCESS","The purpose of this registration form is to list all Managed Access Programs (MAPs) related to LNP023, Iptacopan",[36,37],"C3 Glomerulopathy (C3G)","Paroxysmal Nocturnal Hemoglobinuria (PNH)",[39,40,41,42,11,14],"C3 glomerulopathy (C3G)","Paroxysmal nocturnal hemoglobinuria (PNH)","MAP","Manage access program","AVAILABLE","2025-12-01",{"date":46,"type":47},"2025-12-05","ACTUAL",{"name":22,"class":6}]